|
|
||||||||
Articles |
Angiogenesis is implicated in several pathological conditions, such as inflammation and tumor growth. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is a potent stimulator of endothelial cell proliferation in vitro and in vivo. The present work aimed to compare VEGF expression in human normal thyroid glands, thyroiditis tissue and thyroid carcinomas using immunohistochemistry and in situ hybridization (ISH). Both chronic lymphocytic thyroiditis and differentiated thyroid carcinomas were found to strongly express VEGF mRNA and encode larger amounts of VEGF than normal thyroid tissue as attested by a VEGF immunostaining score. In addition, tumor samples from patients with metastases showed a higher immunostaining score than their non-metastatic counterparts (P<0.05). Carcinomas with the greatest contents of VEGF mRNA and VEGF protein had the most intense mitogenic activity. Special focus on endothelial cells showed intense mitogenic activity in neoplastic tissues in contrast to the total quiescence of endothelial cells in non-tumoral tissues. An intense VEGF production by differentiated thyroid carcinoma, attested either by a higher immunostaining score or a strong VEGF mRNA expression using ISH, could be a promising marker of tumor aggressiveness and may also be useful as a predictor of metastatic potential.
This article has been cited by other articles:
![]() |
E. E.W. Cohen, L. S. Rosen, E. E. Vokes, M. S. Kies, A. A. Forastiere, F. P. Worden, M. A. Kane, E. Sherman, S. Kim, P. Bycott, et al. Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study J. Clin. Oncol., October 10, 2008; 26(29): 4708 - 4713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Joao Bugalho, D. Madureira, C. Espadinha, A. Paula Font, and L. G Sobrinho Serum vascular endothelial growth factor levels in patients with medullary thyroid carcinoma Eur. J. Endocrinol., August 1, 2008; 159(2): 167 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al. Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Randi, M. Ferraroni, R. Talamini, W. Garavello, S. Deandrea, A. Decarli, S. Franceschi, and C. La Vecchia Glycemic index, glycemic load and thyroid cancer risk Ann. Onc., February 1, 2008; 19(2): 380 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-J. Hsiao, M.-Y. Lu, F.-Y. Chiang, S.-J. Shin, Y.-D. Tai, and S.-H. H. Juo Vascular endothelial growth factor gene polymorphisms in thyroid cancer J. Endocrinol., November 1, 2007; 195(2): 265 - 270. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Klubo-Gwiezdzinska, R. Junik, E. Kopczynska, O. Juraniec, and H. Kardymowicz The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter Eur. J. Endocrinol., October 1, 2007; 157(4): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
N G. de la Torre, I Buley, J A H Wass, and H E Turner Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr. Relat. Cancer, September 1, 2006; 13(3): 931 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hoffmann, L. C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, and A. Zielke Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cells in Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6139 - 6145. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ye, C. Feng, S. Wang, K. Z. Q. Wang, N. Huang, X. Liu, Y. Lin, and M. Li sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma Endocrinology, February 1, 2004; 145(2): 817 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Sorvillo, G. Mazziotti, A. Carbone, M. Piscopo, M. Rotondi, M. Cioffi, P. Musto, B. Biondi, S. Iorio, G. Amato, et al. Recombinant Human Thyrotropin Reduces Serum Vascular Endothelial Growth Factor Levels in Patients Monitored for Thyroid Carcinoma Even in the Absence of Thyroid Tissue J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4818 - 4822. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Gerard, C. Daumerie, C. Mestdagh, S. Gohy, C. de Burbure, S. Costagliola, F. Miot, M.-C. Nollevaux, J.-F. Denef, J. Rahier, et al. Correlation between the Loss of Thyroglobulin Iodination and the Expression of Thyroid-Specific Proteins Involved in Iodine Metabolism in Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4977 - 4983. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ye, C. Feng, S. Wang, X. Liu, Y. Lin, and M. Li Antiangiogenic and Antitumor Effects of Endostatin on Follicular Thyroid Carcinoma Endocrinology, September 1, 2002; 143(9): 3522 - 3528. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Tuttle, M. Fleisher, G. L. Francis, and R. J. Robbins Serum Vascular Endothelial Growth Factor Levels Are Elevated in Metastatic Differentiated Thyroid Cancer but Not Increased by Short-Term TSH Stimulation J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1737 - 1742. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Klein, J.-M. Vignaud, V. Hennequin, B. Toussaint, L. Bresler, F. Plénat, J. Leclère, A. Duprez, and G. Weryha Increased Expression of the Vascular Endothelial Growth Factor Is a Pejorative Prognosis Marker in Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 656 - 658. [Abstract] [Full Text] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |